Moderna seeks to use vaccine for adolescents

Paola Ditto
Giugno 7, 2021

The Company also plans to submit for an emergency use authorization (EUA) with the U.S. Food and Drug Administration (FDA) to expand the authorized use of its vaccine to adolescents.

In a statement on Monday, Moderna said it had filed data for a conditional marketing approval in the 27-nation European Union bloc to expand its coronavirus vaccine to children, beyond the green light it received in January for use in adults 18 and over.

In May, the Company announced that the Phase 2/3 TeenCOVE study of Moderna's COVID-19 vaccine in adolescents met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination.

On June 3, Provincial Health Officer Dr. Bonnie Henry announced the Province will proceed with offering patients who received their first COVID-19 immunization of an AstraZeneca vaccine to have either a second dose of AstraZeneca or one of the two mRNA vaccines now available in B.C. - Pfizer/BioNTech and Moderna. The company also intends to submit data for an emergency use authorization in the US for this age group.

Starting Monday, people in British Columbia who initially received the AstraZeneca COVID-19 vaccine will be able to book their second dose.

Teens are much less susceptible to COVID than older age groups, and the main reason to vaccinate them is to drive down transmission.

The two-shot Moderna regime is around 90 percent effective against symptomatic COVID-19 and 95 percent effective against severe disease.

The study involved 3,732 participants between the ages of 12 and 18 in the U.S. Moderna says its vaccine was "generally well tolerated" and that no significant concerns have been identified so far.

Last month, the American Academy of Pediatrics called the authorization of the Pfizer COVID vaccine for adolescents an important tool for more schools to return to in-person learning this fall.

Download the Eyewitness News app to your iOS or Android device.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE